ATE424469T1 - Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung - Google Patents
Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendungInfo
- Publication number
- ATE424469T1 ATE424469T1 AT05766789T AT05766789T ATE424469T1 AT E424469 T1 ATE424469 T1 AT E424469T1 AT 05766789 T AT05766789 T AT 05766789T AT 05766789 T AT05766789 T AT 05766789T AT E424469 T1 ATE424469 T1 AT E424469T1
- Authority
- AT
- Austria
- Prior art keywords
- disorder
- gene
- autism
- diagnosis
- prevention
- Prior art date
Links
- 206010003805 Autism Diseases 0.000 title abstract 4
- 208000020706 Autistic disease Diseases 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 title abstract 2
- 102100024923 Protein kinase C beta type Human genes 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 101150084750 1 gene Proteins 0.000 abstract 1
- 108700028369 Alleles Proteins 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000030979 Language Development disease Diseases 0.000 abstract 1
- 208000036626 Mental retardation Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000012202 Pervasive developmental disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 208000024825 childhood disintegrative disease Diseases 0.000 abstract 1
- 210000000349 chromosome Anatomy 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58413204P | 2004-07-01 | 2004-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE424469T1 true ATE424469T1 (de) | 2009-03-15 |
Family
ID=34982198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05766789T ATE424469T1 (de) | 2004-07-01 | 2005-06-30 | Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20080193464A1 (de) |
| EP (1) | EP1761650B1 (de) |
| JP (1) | JP2008504838A (de) |
| AT (1) | ATE424469T1 (de) |
| AU (1) | AU2005258841B2 (de) |
| CA (1) | CA2571370A1 (de) |
| DE (1) | DE602005013080D1 (de) |
| DK (1) | DK1761650T3 (de) |
| IL (1) | IL179831A (de) |
| WO (1) | WO2006003523A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE482290T1 (de) * | 2005-03-24 | 2010-10-15 | Integragen Sa | Ein transmembranprotein kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung |
| US20070292962A1 (en) * | 2006-04-10 | 2007-12-20 | Duke University | Methods and compositions for genetic markers for autism |
| WO2008126932A2 (en) * | 2007-04-09 | 2008-10-23 | Riken | Epigenetical regulation of brain plasticity |
| US20100248235A1 (en) * | 2007-10-04 | 2010-09-30 | Scherer Stephen W | Biomarkers for autism spectrum disorders |
| WO2011022292A2 (en) * | 2009-08-19 | 2011-02-24 | Lunera Research, Inc. | Method of treating bipolar disorder or depression using an antiestrogen |
| EP2773212B1 (de) * | 2011-10-31 | 2024-08-07 | The Johns Hopkins University | Verfahren und zusammensetzungen zur behandlung von autismus |
| EP2724721A1 (de) * | 2012-10-26 | 2014-04-30 | Matentzoglu, Konstantin | Zusammensetzung zur Verwendung bei der Behandlung des Angelman-Syndroms und/oder von autistischen Spektrumsstörungen, die Verwendung einer solchen Zusammensetzung und ein Verfahren zur Herstellung eines Medikamentes für die Behandlung des Angelman-Syndroms und/oder von autistischen Spektrumsstörungen |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| CA2156725A1 (en) | 1993-02-22 | 1994-09-01 | Warren S. Pear | Production of high titer helper-free retroviruses by transient transfection |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| JP2006515508A (ja) * | 2002-10-23 | 2006-06-01 | エクセリクシス， インク． | 分枝形態形成のモディファイヤーとしてのｍａｐｋ７及び使用方法 |
-
2005
- 2005-06-30 WO PCT/IB2005/002381 patent/WO2006003523A2/en active Application Filing
- 2005-06-30 JP JP2007519916A patent/JP2008504838A/ja not_active Ceased
- 2005-06-30 AU AU2005258841A patent/AU2005258841B2/en not_active Ceased
- 2005-06-30 DE DE602005013080T patent/DE602005013080D1/de not_active Expired - Lifetime
- 2005-06-30 AT AT05766789T patent/ATE424469T1/de active
- 2005-06-30 DK DK05766789T patent/DK1761650T3/da active
- 2005-06-30 US US11/570,480 patent/US20080193464A1/en not_active Abandoned
- 2005-06-30 EP EP05766789A patent/EP1761650B1/de not_active Expired - Lifetime
- 2005-06-30 CA CA002571370A patent/CA2571370A1/en not_active Abandoned
-
2006
- 2006-12-04 IL IL179831A patent/IL179831A/en not_active IP Right Cessation
-
2010
- 2010-03-03 US US12/716,538 patent/US20100240539A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL179831A0 (en) | 2007-05-15 |
| US20080193464A1 (en) | 2008-08-14 |
| EP1761650B1 (de) | 2009-03-04 |
| JP2008504838A (ja) | 2008-02-21 |
| WO2006003523A8 (en) | 2006-03-02 |
| EP1761650A2 (de) | 2007-03-14 |
| WO2006003523A3 (en) | 2006-05-18 |
| AU2005258841B2 (en) | 2010-07-01 |
| IL179831A (en) | 2011-06-30 |
| DK1761650T3 (da) | 2009-06-29 |
| DE602005013080D1 (de) | 2009-04-16 |
| WO2006003523A2 (en) | 2006-01-12 |
| CA2571370A1 (en) | 2006-01-12 |
| AU2005258841A1 (en) | 2006-01-12 |
| US20100240539A1 (en) | 2010-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL179831A0 (en) | Human autism susceptibility gene encoding prkcb1 and uses thereof | |
| IL179751A0 (en) | Human autism predisposition gene encoding a transcription factor and uses thereof | |
| Jiang et al. | Transcriptomic and functional studies reveal undermined chemotactic and angiostimulatory properties of aged microglia during stroke recovery | |
| Kálmán et al. | Human dermal fibroblasts in psychiatry research | |
| PH12013500615A1 (en) | Phosphospecific antibodies recognising tau | |
| WO2014009733A3 (en) | Therapeutic targets for alzheimer's disease | |
| WO2006087634A3 (en) | Uses of human autism susceptibility gene encoding a kinase | |
| ATE431855T1 (de) | Menschliches autismus-suszeptibilitätsgen und verwendungen davon | |
| Ben‐Reuven et al. | Modeling the autistic cell: iPSCs recapitulate developmental principles of syndromic and nonsyndromic ASD | |
| WO2006090288A3 (en) | Human autism susceptibility genes encoding a neurotransmitter transporter and uses thereof | |
| ATE457985T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| GB2473579A (en) | Stat3 and TYK2 as drug targets for neurodegenerative diseases | |
| ATE482290T1 (de) | Ein transmembranprotein kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung | |
| Rikos et al. | TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort | |
| WO2010121834A3 (en) | Irak kinase family as novel target and biomarker for alzheimer | |
| WO2001020025A3 (en) | Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications | |
| Edgünlü et al. | A study of the impact of death receptor 4 (DR4) gene polymorphisms in Alzheimer’s disease | |
| JP2017500306A5 (de) | ||
| WO2006003526A3 (en) | Human autism susceptibility gene encoding otoa and uses thereof | |
| ATE471322T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| Mohammad Jafari et al. | Can Cerebellar Neurodevelopmental Disorders Affect Behavioral Disorders or Vice Versa? | |
| Youssof et al. | Potential role of serotonin transporter gene (5-Htt) polymorphism in temporal lobe epilepsy susceptibility in egyptian patients. | |
| ATE443160T1 (de) | Für einen spannungsgesteuerten kaliumkanal kodierendes humanes adipositas- suszeptibilitätssgen und dessen verwendung | |
| PH12013501724A1 (en) | Glycine transporter-inhibiting substances | |
| TW200801190A (en) | Regulators of protein misfolding and aggregation and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1761650 Country of ref document: EP |